Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 2001 Sep;85(6):798–802. doi: 10.1054/bjoc.2001.2001

Salvage chemotherapy with high-dose leucovorin (LV) and 48-hour continuous infusion (CI) of 5-fluorouracil (5-FU) in combination with conventional doses of cyclophosphamide (CPM) in patients with metastatic breast cancer (MBC) pretreated with anthracycline and taxanes

K Kalbakis 1, Ch Kouroussis 1, S Kakolyris 1, D Mavroudis 1, J Souglakos 1, S Agelaki 1, L Vamvakas 1, M Christodoulakis 2, K Stylianou 1, V Georgoulias 1
PMCID: PMC2375071  PMID: 11556827

Abstract

The purpose of this study was to evaluate the activity and tolerance of high-dose leucovorin (LV) and infusional 5-fluorouracil (5-FU) in combination with conventional doses of cyclophosphamide (CPM) as salvage chemotherapy in patients with metastatic breast cancer (MBC) pretreated with anthracyclines and taxanes. 41 patients (median age 59 years) with MBC refractory or resistant to anthracyclines and taxanes were enrolled. The patients' performance status (WHO) was 0 in 10 patients (24%), 1 in 22 (54%), and 2 in 9 (22%). 30 (73%) patients had received 2 or more prior chemotherapy regimens. Cyclophosphamide (600 mg m−2) was given i.v. bolus on day 1 and LV (500 mg m−2 d−1) as a 2-h infusion followed by 5-FU (1.5 g m−2 d−1) over a 22 h c.i. for 2 consecutive days. Cyclophosphamide was administered every 28 days while 5-FU/LV every 14 days. In an intention-to-treat analysis, complete response (CR) was achieved in 2 (4.9%) patients and partial response (PR) in 9 (22%) (overall response rate 26.9%; 95% CI: 13.27–40.39%). Stable disease (SD) and progressive disease (PD) were observed in 9 (22%) and 21 (51%) patients, respectively. The overall response rate was 6% and 40% in patients with primary and secondary resistance to anthracyclines/taxanes, respectively (P = 0.047). The median duration of response and the median time to disease progression was 8 and 9.5 months, respectively. The median overall survival was 13 months and the probability for 1-year survival 51%. Grade 3/4 neutropenia occurred in 9 (22%) patients and 4 (9%) patients developed grade 3/4 thrombocytopenia. Non-haematological toxicity was mild. There were no cases of febrile neutropenia, toxic deaths or treatment-related hospital admissions due to toxicity. The combination of high-dose 5-FU/LV with conventional doses of cyclophosphamide is a well tolerated and effective salvage regimen in patients with MBC heavily pretreated with both anthracyclines and taxanes. © 2001 Cancer Research Campaignhttp://www.bjcancer.comhttp://www.bjcancer.com

Keywords: breast cancer, salvage chemotherapy, cyclophosphamide, 5-fluorouracil, leucovorin, anthracycline/taxane resistance

Full Text

The Full Text of this article is available as a PDF (49.6 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ajani J. A., Welch S. R., Raber M. N., Fields W. S., Krakoff I. H. Comprehensive criteria for assessing therapy-induced toxicity. Cancer Invest. 1990;8(2):147–159. doi: 10.3109/07357909009017560. [DOI] [PubMed] [Google Scholar]
  2. Cameron D. A., Gabra H., Leonard R. C. Continuous 5-fluorouracil in the treatment of breast cancer. Br J Cancer. 1994 Jul;70(1):120–124. doi: 10.1038/bjc.1994.259. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Chang A. Y., Most C., Pandya K. J. Continuous intravenous infusion of 5-fluorouracil in the treatment of refractory breast cancer. Am J Clin Oncol. 1989 Oct;12(5):453–455. doi: 10.1097/00000421-198910000-00019. [DOI] [PubMed] [Google Scholar]
  4. Conte P. F., Baldini E., Gennari A., Michelotti A., Salvadori B., Tibaldi C., Danesi R., Innocenti F., Gentile A., Dell'Anna R. Dose-finding study and pharmacokinetics of epirubicin and paclitaxel over 3 hours: a regimen with high activity and low cardiotoxicity in advanced breast cancer. J Clin Oncol. 1997 Jul;15(7):2510–2517. doi: 10.1200/JCO.1997.15.7.2510. [DOI] [PubMed] [Google Scholar]
  5. Gianni L., Munzone E., Capri G., Fulfaro F., Tarenzi E., Villani F., Spreafico C., Laffranchi A., Caraceni A., Martini C. Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: high antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study. J Clin Oncol. 1995 Nov;13(11):2688–2699. doi: 10.1200/JCO.1995.13.11.2688. [DOI] [PubMed] [Google Scholar]
  6. Hansen R., Quebbeman E., Beatty P., Ritch P., Anderson T., Jenkins D., Frick J., Ausman R. Continuous 5-fluorouracil infusion in refractory carcinoma of the breast. Breast Cancer Res Treat. 1987 Nov;10(2):145–149. doi: 10.1007/BF01810577. [DOI] [PubMed] [Google Scholar]
  7. Jabboury K., Holmes F. A., Hortobagyi G. 5-Fluorouracil rechallenge by protracted infusion in refractory breast cancer. Cancer. 1989 Aug 15;64(4):793–797. doi: 10.1002/1097-0142(19890815)64:4<793::aid-cncr2820640404>3.0.co;2-8. [DOI] [PubMed] [Google Scholar]
  8. Lokich J. J., Ahlgren J. D., Gullo J. J., Philips J. A., Fryer J. G. A prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: a Mid-Atlantic Oncology Program Study. J Clin Oncol. 1989 Apr;7(4):425–432. doi: 10.1200/JCO.1989.7.4.425. [DOI] [PubMed] [Google Scholar]
  9. Mavroudis D., Malamos N., Alexopoulos A., Kourousis C., Agelaki S., Sarra E., Potamianou A., Kosmas C., Rigatos G., Giannakakis T. Salvage chemotherapy in anthracycline-pretreated metastatic breast cancer patients with docetaxel and gemcitabine: a multicenter phase II trial. Greek Breast Cancer Cooperative Group. Ann Oncol. 1999 Feb;10(2):211–215. doi: 10.1023/a:1008315723253. [DOI] [PubMed] [Google Scholar]
  10. Piccart M. J., Raymond E., Aapro M., Eisenhauer E. A., Cvitkovic E. Cytotoxic agents with activity in breast cancer patients previously exposed to anthracyclines: current status and future prospects. Eur J Cancer. 1995;31A Suppl 7:S1–10. doi: 10.1016/0959-8049(95)00266-l. [DOI] [PubMed] [Google Scholar]
  11. Porkka K., Blomqvist C., Rissanen P., Elomaa I., Pyrhönen S. Salvage therapies in women who fail to respond to first-line treatment with fluorouracil, epirubicin, and cyclophosphamide for advanced breast cancer. J Clin Oncol. 1994 Aug;12(8):1639–1647. doi: 10.1200/JCO.1994.12.8.1639. [DOI] [PubMed] [Google Scholar]
  12. Ravdin P. M., Burris H. A., 3rd, Cook G., Eisenberg P., Kane M., Bierman W. A., Mortimer J., Genevois E., Bellet R. E. Phase II trial of docetaxel in advanced anthracycline-resistant or anthracenedione-resistant breast cancer. J Clin Oncol. 1995 Dec;13(12):2879–2885. doi: 10.1200/JCO.1995.13.12.2879. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES